European journal of cancer (Oxford, England : 1990)HumansRamucirumabPaclitaxelFemaleAntineoplastic Combined Chemotherapy Protocols
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial.
Eleonora Cristarella, Margherita Ambrosini, Massimo Di Maio, Sara Lonardi, Ferdinando De Vita, Samantha Di Donato, Elisa Giommoni, Andrea Spallanzani, Alessandro Bittoni, Claudio Chini, Antonia Strippoli, Tiziana Pia Latiano, Oronzo Brunetti, Stefano Tamberi, Giovanni Gerardo Cardellino
Published: 202510.1016/j.ejca.2025.116060
Abstract
BACKGROUND: In the ARMANI trial, switch maintenance with paclitaxel plus ramucirumab improved progression-free survival and overall survival versus continuation of oxaliplatin-based chemotherapy in patients with HER2-negative advanced gastric or gast…
Preview only. Read the full abstract at the source